Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis

Hongtu GU; Honglian GUI; Lieming XU; Qing GUO; Qing XIE; Changqing ZHAO

doi:10.3969/j.issn.1001-5256.2021.02.013

Volume 37 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(2): 309-313

PDF( 1871 KB)

Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2021.02.013

Hongtu GU^{1, 2, 3},
Honglian GUI⁴,
Lieming XU^{1, 2, 3},
Qing GUO⁴,
Qing XIE^{4
,
,},
Changqing ZHAO^{1, 2, 3
,
,}

1.
Department of Liver Cirrhosis, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
3.
Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai 201203, China
4.
Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received Date: 2020-08-28
Accepted Date: 2020-09-30
Published Date: 2021-02-20

Abstract

Abstract

Objective To investigate the efficacy and safety of Fuzheng Huayu tablets (FZHY) combined with entecavir (ETV) in the treatment of chronic hepatitis B (CHB) liver fibrosis. Methods A total of 52 patients with CHB liver fibrosis with an Ishak stage of ≥F3 who were treated in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from April 2011 to January 2013 were enrolled and divided into FZHY combined with ETV group (combination group) and placebo combined with ETV group (control group), with 26 patients in each group, and the course of treatment was 48 weeks for both groups. Liver biopsy was performed before and after these treatment; clinical outcome was determined based on the reversal rate of Ishak stage for liver fibrosis and the improvement rate of histological activity index (HAI) for inflammation grade, and safety was evaluated based on electrocardiographic findings. Three datasets (full analysis set, per-protocol set, and safety dataset) were identified for analysis; the t-test or the Wilcoxon test was used for comparison of continuous data between two groups, and the CMH chi-square test, the chi-square test, or the Fisher's exact test was used for comparison of categorical data between groups. Results Of all 52 patients, 46 underwent the two liver biopsies before and after treatment, with 22 in the combination group and 24 in the control group. At week 48 of treatment, there was a significant difference in the proportion of patients with Ishak stage reduced by ≥1 stage between the combination group and the control group (81.8% vs 54.2%, χ²=5.297, P=0.021). There was also a significant difference in the improvement rate of HAI grade between the combination group and the control group were (59.1% vs 25.0%, χ²=6.822, P=0.009). There were no significant differences between the two groups in the incidence rates of adverse events and serious adverse events, the safety analysis of vital signs, and laboratory safety indicators (all P > 0.05). Conclusion FZHY combined with ETV has significant advantages over ETV alone in improving liver fibrosis and inflammation, and antiviral therapy combined with anti-fibrosis therapy can bring better hepatic histological improvement for CHB patients. FZHY combined with ETV has good safety in the treatment of patients with CHB liver fibrosis.
- Hepatitis B, Chronic,
- Liver Cirrhosis,
- Entecavir,
- Fuzheng Huayu Tablet,
- Treatment Outcome

FullText(HTML)

References(12)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
[2]	CHANG TT, GISH RG, de MAN R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J]. N Engl J Med, 2006, 354(10): 1001-1010. DOI: 10.1056/NEJMoa051285
[3]	XU B, LIN L, XU G, et al. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2015, 30(2): 372-378. DOI: 10.1111/jgh.12718
[4]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.07.007 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007
[5]	XIE AZ, LYU C, SHI QL, et al. Research progress on prevention and treatment of liver fibrosis by traditional Chinese medicine[J]. China Med Herald, 2020, 17(17): 34-37. (in Chinese) 谢爱泽, 吕超, 石清兰, 等. 中医药防治肝纤维化机制的研究进展[J]. 中国医药导报, 2020, 17(17): 34-37.
[6]	CAO L, GUO RW, GAO YQ, et al. Research progress of integrated traditional Chinese and Western medicine in the treatment of hepatic fibrosis induced by chronic hepatitis B[J]. China Med Herald, 2019, 16(25): 37-40. (in Chinese) 曹林, 郭若闻, 高月求, 等. 中西医结合治疗慢性乙型肝炎肝纤维化的研究进展[J]. 中国医药导报, 2019, 16(25): 37-40.
[7]	PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort[J]. J Viral Hepat, 2015, 22(2): 120-127. DOI: 10.1111/jvh.12283
[8]	ZHAO CQ, XU LM. Clinical effects of Fuzhen Huayu preparations on anti-hepatic ifbrosis and chronic liver diseases[J]. Shanghai Med Pharm J, 2016, 37(13): 17-23, 36. (in Chinese) 赵长青, 徐列明. 扶正化瘀制剂抗肝纤维化和治疗慢性肝病的临床疗效[J]. 上海医药, 2016, 37(13): 17-23, 36.
[9]	GE XJ, ZHAO CQ, XU LM. Effect of Fuzheng Huayu capsules on survival rate of patients with liver cirrhosis[J]. Chin J Hepatol, 2017, 25(11): 834-840. (in Chinese) DOI: 10.3760/cma.j.issn.1007-3418.2017.11.007 戈雪婧, 赵长青, 徐列明. 扶正化瘀胶囊对肝硬化患者生存率的影响[J]. 中华肝脏病杂志, 2017, 25(11): 834-840. DOI: 10.3760/cma.j.issn.1007-3418.2017.11.007
[10]	WANG T, ZHOU X, LIU H, et al. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis[J]. Phytother Res, 2018, 32(5): 757-768. DOI: 10.1002/ptr.6009
[11]	LAI CL, SHOUVAL D, LOK AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2006, 354(10): 1011-1020. DOI: 10.1056/NEJMoa051287
[12]	CHANG TT, LAI CL, KEW YOON S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 2010, 51(2): 422-430. DOI: 10.1002/hep.23327

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (1221) PDF downloads(86)

Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2021.02.013

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2021.02.013

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content